A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Evotec Se stock. As of the latest transaction made, Citadel Advisors LLC holds 27,460 shares of EVO stock, worth $122,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,460
Previous 11,444 139.95%
Holding current value
$122,746
Previous $54,000 85.19%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.96 - $5.34 $47,407 - $85,525
16,016 Added 139.95%
27,460 $100,000
Q2 2024

Aug 14, 2024

BUY
$4.07 - $7.87 $46,577 - $90,064
11,444 New
11,444 $54,000
Q3 2023

Nov 14, 2023

BUY
$9.63 - $13.36 $118,006 - $163,713
12,254 Added 90.77%
25,754 $254,000
Q2 2023

Aug 14, 2023

BUY
$8.95 - $12.48 $120,824 - $168,480
13,500 New
13,500 $152,000
Q4 2022

Feb 14, 2023

BUY
$7.8 - $9.85 $103,615 - $130,847
13,284 New
13,284 $107,000

Others Institutions Holding EVO

About Evotec SE


  • Ticker EVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 353,904,992
  • Market Cap $1.58B
  • Description
  • Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare di...
More about EVO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.